merger | Science and Enterprise

A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial p… https://t.co/iByygVnB9U
about 17 hours ago
New post on Science and Enterprise: Covid-19 Drug Biotech Raises $300M in IPO https://t.co/zwkRakiFk5 #Science #Business
about 17 hours ago
The Food and Drug Administration plans to use organ-on-chip models to test mechanisms for preventing Covid-19 infec… https://t.co/9zAfSK9Nnt
about 22 hours ago
New post on Science and Enterprise: FDA to Use Lung Chip Model for Covid-19 Testing https://t.co/YGwasY1UUJ #Science #Business
about 22 hours ago
Interim results from a clinical trial show a synthetic antibody drug reduces viral burden and medical visits among… https://t.co/bm7JdQ83hT
about 2 days ago

Bayer Gains Gene Therapy Biotech in $4B Deal

By Alan, on October 26th, 2020%

Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders. . . . → Read More: Bayer Gains Gene Therapy Biotech in $4B Deal

Lilly Gains Neuro Disease Biotech in $1.36B Deal

By Alan, on October 15th, 2020%

Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company developing treatments for neurodegenerative disorders. . . . → Read More: Lilly Gains Neuro Disease Biotech in $1.36B Deal

Heart Disease Biotech Acquired in $13.1B Deal

By Alan, on October 5th, 2020%

A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion. . . . → Read More: Heart Disease Biotech Acquired in $13.1B Deal

Cancer Screening Analytics Company Acquired in $8B Deal

By Alan, on September 21st, 2020%

A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock. . . . → Read More: Cancer Screening Analytics Company Acquired in $8B Deal

Gilead Acquires Cancer Therapy Biotech for $21B

By Alan, on September 14th, 2020%

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

Food Allergy Biotech Acquired for $2.6B

By Alan, on August 31st, 2020%

Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion. . . . → Read More: Food Allergy Biotech Acquired for $2.6B

Sanofi Acquires Immune Disease Biotech in $3.7B Deal

By Alan, on August 17th, 2020%

A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi. . . . → Read More: Sanofi Acquires Immune Disease Biotech in $3.7B Deal

Infographic – Apple Leads in A.I. Acquistions

By Alan, on July 11th, 2020%

Among the tech giants, Apple is the most aggressive in acquiring start-ups developing A.I. applications over the past 10 years. . . . → Read More: Infographic – Apple Leads in A.I. Acquistions

Merck Inks Three Covid-19 Vaccine, Therapy Deals

By Alan, on May 26th, 2020%

Drug maker Merck today gained a new acquisition, along with collaboration and licensing deals, for vaccines and a therapy for Covid-19 infections. . . . → Read More: Merck Inks Three Covid-19 Vaccine, Therapy Deals

Synthetic Bio Cancer Immunotherapy Company Acquired

By Alan, on December 27th, 2019%

A biotechnology company creating synthetic proteins that invoke the immune system to fight cancer is being acquired by drug maker Astellas Pharma. . . . → Read More: Synthetic Bio Cancer Immunotherapy Company Acquired

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise